AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

AstraZeneca has signed a research agreement worth more than $5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the ...

Cambridge: AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group ...

The deal with China’s CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of ...

在制药行业，一则重磅消息正在引发广泛关注：全球知名制药公司阿斯利康（AstraZeneca）与中国领先的制药企业石药集团（CSPC）正式宣布达成一项深度战略合作。这一合作不仅代表着两大制药巨头的强强联手，更将对慢性疾病的治疗产生深远的影响。

The collaboration will focus on identifying pre-clinical candidates for high-priority targets, including a small molecule ...

Friday’s deal with fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in China.

CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...

AstraZeneca said on Friday it has agreed to a research deal with Chinese drugmaker CSPC Pharmaceuticals worth up to $5.22 ...

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.